Ensysce Biosciences, Inc.
Funding history
About Ensysce Biosciences, Inc.
How much funding has Ensysce Biosciences, Inc. raised?
Ensysce Biosciences, Inc. has raised $13.1M in total funding. The most recent round was Series C.
Where is Ensysce Biosciences, Inc. headquartered?
Ensysce Biosciences, Inc. is headquartered in La Jolla, CA.
What problem does Ensysce Biosciences, Inc. solve?
The company states it is committed to stemming the prescription drug abuse epidemic, including the risk of abuse (snorting, injecting, chewing) and overdose from oral prescription drugs.
What's Ensysce Biosciences, Inc.'s solution?
Ensysce develops technology platforms applied to oral prescription drugs: TAAP, which reduces the ability to abuse pills by snorting, extracting, injecting, or chewing them, and MPAR, which adds a layer of protection against overdose.
What makes Ensysce Biosciences, Inc. different?
The company cites FDA 'Fast Track' and 'Breakthrough Therapy' designations for its technology and describes its patented MPAR (Multi-Pill Abuse Resistant) approach as setting it apart from conventional and other abuse-deterrent opioid products.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.